Stockholders' Equity (Details Narrative) - USD ($)					1 Months Ended						3 Months Ended	6 Months Ended
	Aug. 04, 2020	Jul. 14, 2020	Sep. 12, 2019	Jan. 07, 2019	Feb. 28, 2021	Jan. 31, 2021	Jan. 20, 2021	Nov. 30, 2020	Nov. 25, 2019	Aug. 31, 2019	Jan. 31, 2020	Jan. 31, 2021	Jan. 31, 2020	Nov. 17, 2020	Oct. 12, 2020	Sep. 28, 2020	Jul. 31, 2020	Feb. 14, 2020
Stock compensation expense												$ 1,742,050
Stock Issued During Period, Value, Issued for Services											$ 243,600	$ 10,993	$ 243,600
Issuance of common stock payable, shares												3,529,415	436,121
Issuance of common stock payable, amount												$ 1,472,826	$ 936,395
Common stock to be issued												8,572,399	10,079,449
Common stock issued for conversion debt, Shares												5,860,255	5,006,548
Common stock issued for conversion debt, Value												$ 1,127,843	$ 2,904,758
Decrease in derivative liability												$ 537,936	2,276,078
Cancellation of common stock			20,375,900
Common stock, shares outstanding						112,572,514						112,572,514					82,251,801
Common stock, shares issued						112,572,514						112,572,514					82,251,801
Proceeds from issuance of stock												$ 1,164,616	$ 109,770
Warrants issued	30,612,240													4,183,575		29,592,825
Exercise price						$ 0.23						$ 0.23		$ 0.18			$ 2.5
Deemed dividend												$ 1,850,000
Decrease in Accumulated Deficit												$ 1,850,000
Number of subscription receivable, shares					750,000
Number of subscription receivable, value					$ 750,000
Medisource
Common stock issued for acquisition										400,000
Stock Price										$ 2.50
Pantheon [Member]
Common stock issued for acquisition										560,000
Stock Price										$ 2.50
Regentys
LOI Terms				Pursuant to the Company’s acquisition of Regentys on January 7, 2019 to acquire a 51% interest, the Company was issued 12,048,161 shares of Regentys common stock. As of January 31, 2021, Regentys had a total of 18,623,278 shares of common stock and 2,793,192 Series A voting preferred stock for a total of 21,416,470 total voting shares outstanding. As such, there are 9,368,309 of shares that belong to non-controlling interest shareholders which represents a 43.74% non-controlling interest
Olaregen
LOI Terms				Pursuant to the Company’s acquisition of Olaregen on January 7, 2019 to acquire a 51% interest, the Company was issued 3,282,632 shares of Olaregen common stock from Olaregen shareholders. In May 2019, the Company issued 4,000,000 shares of common stock contributed and provided by the Friends of Generex Trust and a $2 million note payable for the acquisition of 592,683 shares of Series A Preferred Stock of Olaregen pursuant to a Stock Purchase Agreement entered into January 14, 2019 subject to the approval of the Board of Directors of Olaregen and consummated on May 10, 2019. The provided shares by the Friends of Generex Trust were already issued and outstanding and did not result in any expense of the Company. Since these shares were transferred, to the shareholders of Olaregen, by an existing shareholder to settle an obligation of the Company, the value of the shares provided by the Friends of the Generex Trust to settle the debt was reflected in the financial statements as an addition to contributed (paid-in) capital.
Common stock, shares outstanding																		5,950,000
NGIO
Common stock, shares outstanding																		2,765,000
NGIO | Series A Super Voting Preferred Stock [Member]
Preferred Stock, shares authorized							100,000
Conversion of shares, shares issued							100,000
Number of shares, converted							300,000,000
Series A Warrants [Member]
Exercise price						0.392						$ 0.392
Series B Warrants [Member]
Exercise price						0.392						0.392
Series C Warrants [Member]
Exercise price						$ 0.539						$ 0.539
Series D Warrants [Member]
Exercise price															$ 0.001	$ 0.001
Share Exchange Agreement | Olaregen
Number of shares exchanged		300,000
Vendors
Stock Issued During Period, Shares Issued for Services						51,130
Stock Issued During Period, Value, Issued for Services						$ 10,993
Oasis Capital, LLC | Equity Purchase Agreement [Member]
Common stock purchased									$ 40,000,000
Number of common stock issued									6,350,000
Purchase price of shares									$ 1,439,940
Transaction cost									$ 20,376
Accredited Investors [Member] | Security Purchase Agreement [Member]
Number of common stock issued	5,102,040
Proceeds from issuance of stock	$ 1,850,000
Attorneys fees	$ 150,000
Shares issued price per share	$ 0.001
Accredited Investors [Member] | Security Purchase Agreement [Member] | Series A Warrants [Member]
Shares reserved for future issuance																10,214,503
Warrants issued	5,102,040															5,112,463
Exercise price	$ 0.392															$ 0.1958
Accredited Investors [Member] | Security Purchase Agreement [Member] | Series B Warrants [Member]
Shares reserved for future issuance																30,643,509
Warrants issued	15,306,122															15,337,389
Accredited Investors [Member] | Security Purchase Agreement [Member] | Series C Warrants [Member]
Shares reserved for future issuance																19,347,053
Warrants issued																9,142,973
Exercise price	$ 0.539															$ 0.28149
Accredited Investors [Member] | Security Purchase Agreement [Member] | Series D Warrants [Member]
Shares reserved for future issuance																9,142,973
Warrants issued																9,142,973
Exercise price	$ 0.001															$ 0.001
Consultants [Member] | Security Purchase Agreement [Member]
Number of common stock issued								284,900